Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II
PHASE3
The aim of this trial is to evaluate the efficacy and safety of 2.5 and 5 m...
Status
Completed
Location
205.419.01058 Boehringer Ingelheim Investigational Site
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)
PHASE3
The trial is a randomised, double-blind, placebo-controlled, parallel-group...
Status
Completed
Location
205.417.01061 Boehringer Ingelheim Investigational Site